hVIVO seals Traws Pharma deal for Phase 2a influenza human challenge trial

Open Orphan Plc ( (GB:HVO) ) just unveiled an update.

hVIVO has signed a clinical trial agreement with U.S.-listed Traws Pharma to run a Phase 2a influenza human challenge study of tivoxavir marboxil, an oral, single-dose antiviral candidate targeting seasonal and avian flu. The randomised, double-blind, placebo-controlled trial will take place at hVIVO’s Canary Wharf quarantine facilities, recruit about 150 healthy volunteers via FluCamp, and use the company’s in-house virology labs, with most revenue expected to be recognised in 2026.

The deal underscores hVIVO’s strategy to leverage its optimised influenza human challenge model and integrated services to deliver faster, controlled efficacy data than traditional field studies, bolstering its position as a full-service clinical development partner. For Traws Pharma, the partnership is intended to efficiently generate robust clinical data on TXM’s safety and effectiveness, supporting its development programme in a large, high-burden respiratory virus market.

The most recent analyst rating on (GB:HVO) stock is a Buy with a £10.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.

Spark’s Take on HVO Stock

According to Spark, TipRanks’ AI Analyst, HVO is a Outperform.

Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.

To see Spark’s full report on HVO stock, click here.

More about Open Orphan Plc

hVIVO plc is a purpose-built, full-service international clinical development partner and the global leader in human challenge trials, serving seven of the world’s ten largest biopharma companies. The group offers an end-to-end platform from preclinical strategy through Phase II trials and specialist laboratory services via its UK and German sites, organised across four pillars: consulting, clinical trials, human challenge trials and laboratories.

Average Trading Volume: 3,326,706

Technical Sentiment Signal: Sell

Current Market Cap: £51.97M

See more insights into HVO stock on TipRanks’ Stock Analysis page.